Saltar al contenido
Merck

Y0001484

Medroxyprogesterone 17-acetate

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Medroxyprogesterone 17-acetate, 17α-Acetoxy-6α-methylprogesterone, 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-acetate, 6α-Methyl-17α-acetoxyprogesterone, 6α-Methyl-17α-hydroxyprogesterone acetate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C24H34O4
Número de CAS:
Peso molecular:
386.52
Beilstein:
2066112
Número MDL:
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

medroxyprogesterone

fabricante / nombre comercial

EDQM

mp

206-207 °C (lit.)

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

[H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4(OC(C)=O)C(C)=O

InChI

1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1

Clave InChI

PSGAAPLEWMOORI-PEINSRQWSA-N

Información sobre el gen

human ... PGR(5241)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Medroxyprogesterone acetate for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Pictogramas

Health hazard

Palabra de señalización

Warning

Frases de peligro

Clasificaciones de peligro

Aquatic Chronic 4 - Carc. 2

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Edith R Guilbert et al.
Contraception, 79(3), 167-177 (2009-02-03)
In the fall of 2007, the controversy about the contraceptive use of depot-medroxyprogesterone acetate (DMPA) and its potential impact on skeletal health reached the media in the province of Quebec, Canada, thereby becoming a matter of concern for the lay
J Mitsushita et al.
Gynecologic oncology, 79(1), 129-132 (2000-09-28)
Successful pregnancies after conservative progestin treatment to young women with endometrial carcinoma have recently been reported. However, it is not known for certain whether the lesion is completely eradicated in such patients. We present a case of residual endometrial carcinoma
Andrew M Kaunitz et al.
Contraception, 77(2), 67-76 (2008-01-30)
While depot medroxyprogesterone acetate (DMPA) is a highly effective contraceptive used by millions of women, its use is associated with bone mineral density (BMD) loss, raising concerns about long-term risk of osteoporosis and/or fractures. We conducted a systematic review of
R Kent Hermsmeyer et al.
Nature clinical practice. Cardiovascular medicine, 5(7), 387-395 (2008-06-04)
Heart disease presentation can differ between the sexes because nonobstructive coronary disease and angina unrelated to exercise are considerably more prevalent in women than in men. When the outcomes of large, randomized, controlled trials failed to demonstrate cardiac risk protection
Frank Z Stanczyk et al.
The Journal of steroid biochemistry and molecular biology, 142, 30-38 (2013-12-03)
Medroxyprogesterone acetate (MPA) has been in clinical use for over 30 years, and was generally considered to be safe until the results of long-term studies of postmenopausal hormone therapy (HT) using treatment with conjugated equine estrogens (CEE) combined with MPA

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico